A Study of Early Cancer Detection in People at High Risk of Developing Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. In this study, researchers will look at whether a combination of the following types of imaging with blood tests can detect PDAC in pancreatic cysts:

The ImmunoPET scan (immune-positron emission tomography scan) with the imaging agent 89Zr-DFO-HuMab-5B1
The HP MRI scan (hyperpolarized pyruvate magnetic resonance imaging scan)
- EligibilityCriteria: Inclusion Criteria:  Men and women aged >18 years Pancreatic cystic neoplasm deemed to be high risk and requiring surgical resection Able to provide informed consent  Exclusion Criteria:  Pathologic evidence of pancreatic cancer Pregnant or breast-feeding patients Refusal or inability to tolerate scan (eg anxiety or claustrophobia) Inability to lay flat or meet the standard requirements of traditional MRI  Hepatic function from assays obtained within 6 weeks prior to the study enrollment. For each patient, the upper limit of normal (ULN) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay  Bilirubin > 1.5 x ULN AST/ALT > 2.5 x ULN Albumin < 3 g/dL GGT > 2.5 x ULN if Alkaline Phosphatase > 2.5 x ULN Renal function with Creatinine > 1.5 x ULN or creatinine clearance < 60 mL/min, from assays obtained within 6 weeks prior to study enrollment Cardiac: congestive heart failure with New York Heart Association (NYHA) status ≥2, poorly controlled hypertension, a history of clinically significant EKG abnormalities, or myocardial infarction within 6 months of study enrollment. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Potential research subjects will be identified by a member of the patient's treatment team, the protocol investigator, or research team at Memorial Sloan Kettering (MSK). - SamplingMethod: Non-Probability Sample